Goldman Sachs
VKTX icon

Goldman Sachs’s Viking Therapeutics VKTX Stock Holding History

Goldman Sachs’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,500
Closed -$897K – 7017
2025
Q4 		$897K Buy
+25,500
New +$904K ﹤0.01% 5216
2025
Q1 		– Sell
-35,000
Closed -$1.41M – 6418
2024
Q4 		$1.41M Buy
+35,000
New +$2M ﹤0.01% 4576
2024
Q3 		– Sell
-20,000
Closed -$1.06M – 6089
2024
Q2 		$1.06M Buy
+20,000
New +$1.31M ﹤0.01% 4391

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs's VKTX Position: Q1 2026 in Review

Goldman Sachs increased its Viking Therapeutics (VKTX) stake by 15% in Q1 2026, buying an estimated $4.11M and bringing the position to 960,570 shares worth $31.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2016.

Goldman Sachs first reported a position in VKTX in Q2 2015 and has held it in 37 quarters since. The position peaked at $56.9M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Goldman Sachs held 960,570 shares of Viking Therapeutics worth $31.3M as of Q1 2026.
  • Goldman Sachs bought 127,919 Viking Therapeutics shares in Q1 2026, an estimated $4.11M.
  • Viking Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2016 holding.
  • Goldman Sachs first reported a position in Viking Therapeutics in Q2 2015 and has held it in 37 quarters since.
  • Goldman Sachs's Viking Therapeutics position peaked at $56.9M in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.